Grunenthal GmbH - Strategic SWOT Analysis Review

1 of 5

FEATURED COMPANIES

  • Endo Pharmaceuticals Inc
  • Mibe GmbH Arzneimittel
  • Pensa Pharma GmbH
  • Purdue Pharma LP
  • TAD Pharma GmbH
  • MORE
Grunenthal GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Summarization of the company’s business strategy.
  • SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
Highlights

Grunenthal GmbH (Grunenthal) is a research-oriented pharmaceutical company. It researches, develops, produces and markets products for the treatment of pain and innovative formulations of established active substances. The company provides new chemical entities including opioids for moderate to severe pain, vanilloid receptors and KCNQ channel openers for chronic neuropathic pain; and the Bradykinin receptor for the treatment of chronic diseases with inflammation. Grunenthal also focuses on discovering new methods to treat pain, developing new medical devices, and new platform technologies for drug delivery. The company operates along with its subsidiaries in Europe, Latin America and the US. Grunenthal is headquartered in Aachen, Germany.

Grunenthal GmbH Key Recent Developments

Apr 23, 2018: Grunenthal Names Dr. Philip Just Larsen As Chief Scientific Officer
Nov 16, 2017: Research Consortium led by Grünenthal receives € 2 million grant from the European Fund for Regional Development and the State of North Rhine-Westphalia
Sep 01, 2017: Mark Fladrich Takes office as the New CCO of the Grunenthal Group
Jul 07, 2017: Grünenthal Group: Launch of the Project - Modelling Neuron-glia Networks Into a Drug Discovery Platform for Pain Efficacious Treatments (NGN-PET)
May 23, 2017: Cutting Edge Science in Pain Treatment in Order to Improve Patients' Lives - EFIC-GRUNENTHAL GRANT 2016 Supports Six Young Scientists in Their Advanced Pain Research Projects

Reasons to buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with this detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Endo Pharmaceuticals Inc
  • Mibe GmbH Arzneimittel
  • Pensa Pharma GmbH
  • Purdue Pharma LP
  • TAD Pharma GmbH
  • MORE
Section 1 - About the Company
  • Grunenthal GmbH - Key Facts
  • Grunenthal GmbH - Key Employees
  • Grunenthal GmbH - Key Employee Biographies
  • Grunenthal GmbH - Major Products and Services
  • Grunenthal GmbH - History
  • Grunenthal GmbH - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Grunenthal GmbH - Business Description
  • R&D Overview
  • Grunenthal GmbH - Corporate Strategy
  • Grunenthal GmbH - SWOT Analysis
  • SWOT Analysis - Overview
  • Grunenthal GmbH - Strengths
  • Grunenthal GmbH - Weaknesses
  • Grunenthal GmbH - Opportunities
  • Grunenthal GmbH - Threats
  • Grunenthal GmbH - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Grunenthal GmbH, Recent Deals Summary
Section 4 - Company’s Recent Developments
  • Nov 16, 2017: Research Consortium led by Grünenthal receives € 2 million grant from the European Fund for Regional Development and the State of North Rhine-Westphalia
  • Sep 01, 2017: Mark Fladrich Takes office as the New CCO of the Grunenthal Group
  • Jul 07, 2017: Grünenthal Group: Launch of the Project - Modelling Neuron-glia Networks Into a Drug Discovery Platform for Pain Efficacious Treatments (NGN-PET)
  • May 23, 2017: Cutting Edge Science in Pain Treatment in Order to Improve Patients' Lives - EFIC-GRUNENTHAL GRANT 2016 Supports Six Young Scientists in Their Advanced Pain Research Projects
  • May 10, 2017: Grünenthal Opens Innovation Hub in Boston as Next Step in Strategy to Drive External Innovation in Pain, Specialty Therapeutics and Medical Devices Forward
  • May 09, 2017: Mark Fladrich Appointed New Chief Commercial Officer at Grunenthal
  • May 03, 2017: 23andMe and German Pain Specialist Grunenthal Explore the Genetics of Pain to Help Identify New Treatments for Patients
  • Jan 12, 2017: Grunenthal introduces Latin America’s most modern women’s health products plant
Section 5 - Appendix
  • Methodology
  • About
  • Contact
  • Disclaimer
List of Tables
  • Grunenthal GmbH, Key Facts
  • Grunenthal GmbH, Key Employees
  • Grunenthal GmbH, Key Employee Biographies
  • Grunenthal GmbH, Major Products and Services
  • Grunenthal GmbH, History
  • Grunenthal GmbH, Other Locations
  • Grunenthal GmbH, Subsidiaries
  • Grunenthal GmbH, Key Competitors
  • Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Grunenthal GmbH, Recent Deals Summary
List of Figures
  • Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • TAD Pharma GmbH
  • Mibe GmbH Arzneimittel
  • Mundipharma International Ltd
  • Pensa Pharma GmbH
  • Purdue Pharma LP
  • Endo Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll